Skip to content


  • Poster presentation
  • Open Access

Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis

  • 1, 2,
  • 1,
  • 1 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :P36

  • Published:


  • Public Health
  • Infliximab
  • Cataract
  • Etanercept
  • Uveitis


Chronic uveitis is associated with JIA in about 15–30% of cases. Treatment with anti-TNF agents is very effective in JIA, but their efficacy for uveitis is controversial. We present here the preliminary results of a retrospective case series of uveitis associated of JIA and treated by different anti-TNF.


To evaluate the efficacy of TNF inhibitors in JIA-associated uveitis, as well as report the cases of uveitis associated with the use of anti-TNF.


The data of 16 patients with JIA and uveitis receiving anti-TNF were collected retrospectively in three French centers.


Of the 16 patients, 10 were treated with etanercept (62.5%), 1 with adalimumab (6.25%), and 5 (31.2%) with infliximab. Notably, two cases of uveitis were associated with use of etanercept. In 5 patients (31.2%) the anti-TNF was changed because of lack of efficacy and/or side effects to another one (in 4/5 adalimumab). Ten patients had a complicated uveitis (cataract in 5). The number of relapses of uveitis was 4 ± 1.35 with the first anti-TNF, and 1.3 ± 1.5 with the second one. Remission of uveitis was obtained in 4 cases, 3 of them with adalimumab and one case with etanercept.


Anti-TNF agents have a favourable effect in JIA-associated uveitis, but adalimumab and perhaps infliximab may be more effective than etanercept, during which treatment uveitis may even develop.

Authors’ Affiliations

Hôpital Femme Mère Enfant, Bron, France
Hôpital Cochin, Paris, France


© Rivarola et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.